Furthermore, our study may provide a foundation to accurately classify grade III endometrial tumors based on DHODH overexpression associated with the POLE and POLD1 mutation, which may contribute to the better selection of patients for future therapeutic strategies. This evidence concerns the gene POLE and endometrium neoplasm.